Robalzotan (NAD‐299), a Novel Selective 5‐HT1AReceptor Antagonist

CNS Drug ReviewsVolume 5, Issue 3 p. 213-232 Free Access Robalzotan (NAD-299), a Novel Selective 5-HT 1A Receptor Antagonist Svante B. Ross, Svante B. Ross Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorSeth-Olov Thorberg, Seth-Olov Thorberg Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorEva Jerning, Eva Jerning Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorNina Mohell, Nina Mohell Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorCarina Stenfors, Carina Stenfors Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorCarin Wallsten, Carin Wallsten Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorIngalill Gagner Milchert, Ingalill Gagner Milchert Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorGöran Öjteg, Corresponding Author Göran Öjteg Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenDr. G. Öjteg, AstraZeneca R & D Södertälj, S-151 85 Södertälje, Sweden.Search for more papers by this author Svante B. Ross, Svante B. Ross Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorSeth-Olov Thorberg, Seth-Olov Thorberg Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorEva Jerning, Eva Jerning Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorNina Mohell, Nina Mohell Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorCarina Stenfors, Carina Stenfors Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorCarin Wallsten, Carin Wallsten Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorIngalill Gagner Milchert, Ingalill Gagner Milchert Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenSearch for more papers by this authorGöran Öjteg, Corresponding Author Göran Öjteg Preclinical Research and Development, Astra Arcus AB, Södertälje, SwedenDr. G. Öjteg, AstraZeneca R & D Södertälj, S-151 85 Södertälje, Sweden.Search for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3458.1999.tb00101.xCitations: 24AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.